SINGAPORE, Sept. 17, 2018 /PRNewswire/ -- New four-year
study data shows the significant impact of a pioneering contact
lens management approach to slowing the progression of myopia
(nearsightedness) in children, including those whose treatment
begins later. CooperVision is presenting the multi-year study's
latest outcomes during the BCLA Asia conference in Singapore this week, at which the globally
increasing prevalence of myopia is among the most widely discussed
issues.
The ongoing clinical trial is assessing a specially-designed,
dual-focus myopia control 1-day soft contact lens in reducing the
rate of progression of juvenile-onset myopia. The lens is
commercially available as CooperVision®
MiSight® in select countries.1
"Four-year results on the efficacy of our innovative myopia
control lens represent a landmark in slowing myopia progression.
The treatment is continuing to work for children who have been
wearing MiSight® contact lenses for the entire study,
and their axial length progression in this last year has slowed
further. This illustrates the benefits of beginning myopia
management as early as possible to maximize the benefit," said
Paul Chamberlain, Director of
Research Programs for CooperVision.
After year three, myopia progression slowed in children wearing
the MiSight® contact lens: 59% as measured by mean
cycloplegic spherical equivalent (SE) and 52% as measured by mean
axial elongation of the eye when compared to the children in the
control group wearing a single vision 1-day contact lens.
In year four, children in the original control group were refit
with the myopia control lens, and then continued to be tracked
separately. Use of the dual-focus contact lens — which has
alternating visual correction and treatment zones — was effective
in slowing myopia progression in both groups:
- There was a significant reduction in myopic progression for the
previous single vision 1-day wearers, indicating that
MiSight® contact lenses are also effective when
beginning myopia management at an older age.
- There were no significant differences between groups for change
in Spherical Equivalent Refractive Error and Axial Length over 12
months.
- Axial length growth of 0.07mm in the MiSight® group
and 0.06mm in the previous control group, compared to 0.10mm seen
in the MiSight® group in year three, represents further
myopia slowing as the children age.
- There were no significant differences in myopia progression
rates for two demographically matched populations in their first
versus fourth years of MiSight® contact lens wear.
No other prospective randomized controlled study has offered
conclusive data for such a high degree of continued efficacy in
myopia management using a 1-day soft contact lens over four years.
The contact lens-based approach does not induce common side effects
exhibited by some alternative pharmacological therapies.
The prevalence of myopia is projected to increase from
approximately two billion people worldwide in 2010 to almost five
billion people in 20502, bringing with it near- and
long-term health challenge Not only does it create blurred vision,
but also increases the likelihood of conditions later in life such
as glaucoma, cataract, retinal detachment and myopic maculopathy if
not addressed.
"The four-year results are another great learning for
CooperVision and the entire optical industry on the capability to
slow the progression of myopia in children. Though children benefit
at whatever age the treatment is started, the sooner their myopia
is managed with MiSight® contact lenses, the more effect
and benefit they receive in reducing final levels and the future
risk of related vision impairment issues," said Stuart Cockerill, Senior Director, Myopia
Management.
Physiological changes among 100 myopic children from
Singapore, Canada, England, and Portugal were evaluated during the fourth
year.
1 MiSight® 1 day contact lenses are
currently available for sale in Canada, the United
Kingdom, France,
Spain, Portugal, Netherlands, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong
Kong, Australia and
New Zealand. MiSight®
is not approved in the United
States.
2 Holden et al, Ophthalmology 2016.
About CooperVision
CooperVision, a unit of The Cooper
Companies, Inc. (NYSE: COO), is one of the world's leading
manufacturers of soft contact lenses. The Company produces a full
array of monthly, two-week and daily disposable contact lenses, all
featuring advanced materials and optics. CooperVision has a strong
heritage of solving the toughest vision challenges such as
astigmatism and presbyopia; and offers the most complete collection
of spherical, toric and multifocal products available. Through a
combination of innovative products and focused practitioner
support, the company brings a refreshing perspective to the
marketplace, creating real advantages for customers and wearers.
For more information, visit coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc.
("Cooper") is a global medical device company publicly traded on
the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life
Company™ with a focus on delivering shareholder value. Cooper
operates through two business units, CooperVision and
CooperSurgical. CooperVision brings a refreshing perspective on
vision care with a commitment to developing a wide range of
high-quality products for contact lens wearers and providing
focused practitioner support. CooperSurgical is committed to
advancing the health of families with its diversified portfolio of
products and services focusing on women's health, fertility and
diagnostics. Headquartered in Pleasanton,
Calif., Cooper has more than 12,000 employees with products
sold in over 100 countries. For more information, please visit
www.coopercos.com.
Media Contact
Mike
McDougall, APR, Fellow PRSA
McDougall Communications for CooperVision, Inc.
mike@mcdougallpr.com or +1-585-434-2150
View original
content:http://www.prnewswire.com/news-releases/coopervision-releases-four-year-data-on-landmark-misight-1-day-contact-lens-study-pioneering-approach-slows-myopia-progression-in-children-300713073.html
SOURCE CooperVision